Emcure Pharma Arm Acquires Canada's Cutimed for CAD 5.05 Million, Merges with Mantra
New Delhi: Emcure Pharmaceuticals Limited has announced that its step-down subsidiary, Mantra Pharma Inc., has acquired 100% stake in Canada-based Cutimed Inc. for up to CAD 5.05 million, followed by its amalgamation with Mantra effective April 1, 2026.
The acquisition was executed through a share purchase agreement, making Cutimed a wholly owned step-down subsidiary of Emcure. Immediately after the transaction, Cutimed was merged with Mantra Pharma Inc. through a short-form amalgamation under the Business Corporations Act (Québec), consolidating the group’s Canadian operations.
Cutimed Inc., incorporated in Québec, Canada, is engaged in the development and commercialization of cosmetic and dermatological products, including creams, cleansers, and lip care products. The company primarily operates in the Canadian market and reported an annual turnover of approximately CAD 2.8 million in FY2025, CAD 2.5 million in FY2024, and CAD 2.7 million in FY2023.
The acquisition was completed through cash consideration and does not qualify as a related party transaction. Neither the promoter nor group entities had any prior interest in Cutimed before the deal. The transaction was subject to standard compliance requirements under applicable Canadian laws.
Following the acquisition, the amalgamation between Mantra Pharma Inc. and Cutimed aims to streamline operations and improve administrative efficiencies. Mantra Pharma, which reported an annual turnover of around CAD 81 million, is engaged in the distribution of pharmaceutical and natural health products.
The company stated that the strategic move is aligned with its core business and is expected to strengthen its presence in the Canadian dermatological and cosmetic product segments, supporting its long-term growth strategy.
No consideration was required for the amalgamation as Mantra already held 100% ownership of Cutimed post-acquisition, leading to cancellation of shares held in the subsidiary. The transaction does not result in any change in the shareholding pattern of Emcure Pharmaceuticals.
